Relay Therapeutics (RLAY) Stock Forecast & Price Target

Compare

473 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RLAY Analyst Ratings

Strong Buy

7 Buy

2 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Relay

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RLAY Stock 12 Month Forecast

Average Price Target

$12.43

▲(303.57%Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Relay Therapeutics in the last 3 months. The average price target is $12.43 with a high forecast of $17.00 and a low forecast of $4.00. The average price target represents a 303.57% change from the last price of $3.08.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","18":"$18","5.25":"$5.25","9.5":"$9.5","13.75":"$13.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,5.25,9.5,13.75,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.29,4.344615384615385,5.399230769230769,6.453846153846154,7.508461538461539,8.563076923076924,9.617692307692309,10.672307692307694,11.726923076923079,12.781538461538464,13.836153846153849,14.890769230769234,15.945384615384615,{"y":17,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.29,3.993076923076923,4.696153846153846,5.399230769230769,6.102307692307693,6.805384615384616,7.508461538461539,8.211538461538463,8.914615384615384,9.617692307692309,10.320769230769232,11.023846153846154,11.726923076923079,{"y":12.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.29,3.3446153846153845,3.399230769230769,3.453846153846154,3.5084615384615385,3.563076923076923,3.6176923076923075,3.6723076923076925,3.726923076923077,3.7815384615384615,3.836153846153846,3.890769230769231,3.9453846153846155,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.66,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.41,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.4,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.99,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.79,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.55,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.84,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.67,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.47,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.41,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$17.00

Average Price Target$12.43

Lowest Price Target$4.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

-2.60%

Downside

Reiterated

05/29/25

Relay Therapeutics faces significant financial challenges, with consistent losses and negative cash flow impacting its financial performance. Technical indicators suggest a bearish trend, and valuation metrics highlight difficulties due to a negative P/E ratio. The absence of earnings call and corporate event data leaves these areas unaddressed in the score.

Eric JosephJ.P. Morgan

J.P. Morgan

$21→$11

Buy

257.14%

Upside

Reiterated

05/13/25

Relay Therapeutics (RLAY) PT Lowered to $11 at JPMorganJPMorgan analyst Eric Joseph lowered the price target on Relay Therapeutics (NASDAQ: RLAY) to $11.00 (from $21.00) while maintaining a Overweight rating.

Jason GerberryBank of America Securities

Bank of America Securities

$19→$17

Buy

451.95%

Upside

Reiterated

05/08/25

Analysts Are Bullish on These Healthcare Stocks: Relay Therapeutics (RLAY), Zura Bio (ZURA)

Michael SchmidtGuggenheim

Guggenheim

$30→$10

Buy

224.68%

Upside

Reiterated

05/07/25

Relay Therapeutics price target lowered to $10 from $30 at GuggenheimRelay Therapeutics price target lowered to $10 from $30 at Guggenheim

Robert BurnsH.C. Wainwright

H.C. Wainwright

$16

Buy

419.48%

Upside

Reiterated

05/07/25

Analysts Offer Insights on Healthcare Companies: BioAtla (NASDAQ: BCAB), Relay Therapeutics (NASDAQ: RLAY) and Crispr Therapeutics AG (NASDAQ: CRSP)

Yaron WerberTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/06/25

Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (NASDAQ: CORT), Zimmer Biomet Holdings (NYSE: ZBH) and Relay Therapeutics (NASDAQ: RLAY)

Andrew BerensLeerink Partners

Leerink Partners

$14→$12

Buy

289.61%

Upside

Reiterated

05/06/25

Analysts Conflicted on These Healthcare Names: AnaptysBio (NASDAQ: ANAB), Relay Therapeutics (NASDAQ: RLAY) and Inspire Medical Systems (NYSE: INSP)

Peter LawsonBarclays

Barclays

$17

Buy

451.95%

Upside

Reiterated

05/06/25

Analysts Offer Insights on Healthcare Companies: American Well (NYSE: AMWL), Relay Therapeutics (NASDAQ: RLAY) and Inspire Medical Systems (NYSE: INSP)

Eva Fortea VerdejoWells Fargo

Wells Fargo

Hold

29.87%

Upside

Reiterated

05/05/25

Relay Therapeutics: Awaiting Significant Catalysts Amidst Strong Cash Position and Pipeline Potential

Matthew BieglerOppenheimer

Oppenheimer

―

Hold

―

Reiterated

05/05/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Relay Therapeutics (NASDAQ: RLAY) and AnaptysBio (NASDAQ: ANAB)

Silvan TuerkcanCitizens JMP

Citizens JMP

$21→$12

Buy

289.61%

Upside

Reiterated

02/28/25

Buy Rating for Relay Therapeutics Driven by Strategic Advancements and Promising Clinical Trial DevelopmentsWe maintain our Market Outperform rating ahead of a data update in 2025.

Salveen RichterGoldman Sachs

Goldman Sachs

$20→$18

Buy

484.42%

Upside

Reiterated

02/27/25

Relay Therapeutics (RLAY) PT Lowered to $18 at Goldman SachsGoldman Sachs analyst Salveen Richter lowered the price target on Relay Therapeutics (NASDAQ: RLAY) to $18.00 (from $20.00) while maintaining a Buy rating.

Bradley CaninoStifel Nicolaus

Stifel Nicolaus

$27→$23

Buy

646.75%

Upside

Reiterated

02/27/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Akash TewariJefferies

Jefferies

$17

Buy

451.95%

Upside

Assigned

12/11/24

Jefferies Reaffirms Their Buy Rating on Relay Therapeutics (RLAY)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

-2.60%

Downside

Reiterated

05/29/25

Eric JosephJ.P. Morgan

J.P. Morgan

$21→$11

Buy

257.14%

Upside

Reiterated

05/13/25

Jason GerberryBank of America Securities

Bank of America Securities

$19→$17

Buy

451.95%

Upside

Reiterated

05/08/25

Analysts Are Bullish on These Healthcare Stocks: Relay Therapeutics (RLAY), Zura Bio (ZURA)

Michael SchmidtGuggenheim

Guggenheim

$30→$10

Buy

224.68%

Upside

Reiterated

05/07/25

Relay Therapeutics price target lowered to $10 from $30 at GuggenheimRelay Therapeutics price target lowered to $10 from $30 at Guggenheim

Robert BurnsH.C. Wainwright

H.C. Wainwright

$16

Buy

419.48%

Upside

Reiterated

05/07/25

Analysts Offer Insights on Healthcare Companies: BioAtla (NASDAQ: BCAB), Relay Therapeutics (NASDAQ: RLAY) and Crispr Therapeutics AG (NASDAQ: CRSP)

Yaron WerberTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/06/25

Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (NASDAQ: CORT), Zimmer Biomet Holdings (NYSE: ZBH) and Relay Therapeutics (NASDAQ: RLAY)

Andrew BerensLeerink Partners

Leerink Partners

$14→$12

Buy

289.61%

Upside

Reiterated

05/06/25

Analysts Conflicted on These Healthcare Names: AnaptysBio (NASDAQ: ANAB), Relay Therapeutics (NASDAQ: RLAY) and Inspire Medical Systems (NYSE: INSP)

Peter LawsonBarclays

Barclays

$17

Buy

451.95%

Upside

Reiterated

05/06/25

Analysts Offer Insights on Healthcare Companies: American Well (NYSE: AMWL), Relay Therapeutics (NASDAQ: RLAY) and Inspire Medical Systems (NYSE: INSP)

Eva Fortea VerdejoWells Fargo

Wells Fargo

Hold

29.87%

Upside

Reiterated

05/05/25

Relay Therapeutics: Awaiting Significant Catalysts Amidst Strong Cash Position and Pipeline Potential

Matthew BieglerOppenheimer

Oppenheimer

―

Hold

―

Reiterated

05/05/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Relay Therapeutics (NASDAQ: RLAY) and AnaptysBio (NASDAQ: ANAB)

Silvan TuerkcanCitizens JMP

Citizens JMP

$21→$12

Buy

289.61%

Upside

Reiterated

02/28/25

Buy Rating for Relay Therapeutics Driven by Strategic Advancements and Promising Clinical Trial DevelopmentsWe maintain our Market Outperform rating ahead of a data update in 2025.

Salveen RichterGoldman Sachs

Goldman Sachs

$20→$18

Buy

484.42%

Upside

Reiterated

02/27/25

Bradley CaninoStifel Nicolaus

Stifel Nicolaus

$27→$23

Buy

646.75%

Upside

Reiterated

02/27/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Akash TewariJefferies

Jefferies

$17

Buy

451.95%

Upside

Assigned

12/11/24

Jefferies Reaffirms Their Buy Rating on Relay Therapeutics (RLAY)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Relay Therapeutics

1 Month

xxx

Success Rate

9/21 ratings generated profit

Average Return

-4.70%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of -4.70% per trade.

3 Months

xxx

Success Rate

8/21 ratings generated profit

Average Return

-11.38%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 38.10% of your transactions generating a profit, with an average return of -11.38% per trade.

1 Year

Peter LawsonBarclays

Success Rate

1/12 ratings generated profit

Average Return

-38.27%

reiterated a buy rating 26 days ago

Copying Peter Lawson's trades and holding each position for 1 Year would result in 8.33% of your transactions generating a profit, with an average return of -38.27% per trade.

2 Years

xxx

Success Rate

1/12 ratings generated profit

Average Return

-38.17%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 8.33% of your transactions generating a profit, with an average return of -38.17% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RLAY Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RLAY has received 10 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. RLAY average Analyst price target in the past 3 months is 12.43.

Each month's total comprises the sum of three months' worth of ratings.

RLAY Financial Forecast

RLAY Earnings Forecast

Next quarter’s earnings estimate for RLAY is -$0.49 with a range of -$0.57 to -$0.37. The previous quarter’s EPS was -$0.46. RLAY beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.94% of the time in the same period. In the last calendar year RLAY has Outperformed its overall industry.

RLAY Sales Forecast

Next quarter’s sales forecast for RLAY is $67.00K with a range of $0.00 to $500.00K. The previous quarter’s sales results were $7.68M. RLAY beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.36% of the time in the same period. In the last calendar year RLAY has Outperformed its overall industry.

RLAY Stock Forecast FAQ

What is RLAY’s average 12-month price target, according to analysts?

Based on analyst ratings, Relay Therapeutics’s 12-month average price target is 12.43.

What is RLAY’s upside potential, based on the analysts’ average price target?

Relay Therapeutics has 303.57% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RLAY a Buy, Sell or Hold?

Relay Therapeutics has a consensus rating of Strong Buy which is based on 7 buy ratings, 2 hold ratings and 0 sell ratings.

What is Relay Therapeutics’s price target?

The average price target for Relay Therapeutics is 12.43. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $17.00 ,the lowest forecast is $4.00. The average price target represents 303.57% Increase from the current price of $3.08.

What do analysts say about Relay Therapeutics?

Relay Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of RLAY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Relay Therapeutics (RLAY) Stock Forecast & Price Target

RLAY Analyst Ratings

RLAY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Relay Therapeutics

RLAY Analyst Recommendation Trends

RLAY Financial Forecast

RLAY Earnings Forecast

RLAY Sales Forecast

RLAY Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts